

FOR IMMEDIATE RELEASE

Investors Contact:

Robert G. Burrows
Emergent BioSolutions
Vice President, Investor Relations
+1-301-795-1877
BurrowsR@ebsi.com

Media Contact:

Tracey Schmitt
Emergent BioSolutions
Vice President, Corporate Communications
+1-301-795-1800
SchmittT@ebsi.com

EMERGENT BIOSOLUTIONS EXECUTIVE CHAIRMAN FUAD EL-HIBRI NAMED TECH COUNCIL OF MARYLAND'S EXECUTIVE OF THE YEAR

ROCKVILLE, MD, April 26, 2012 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad El-Hibri, its executive chairman of the board, has been recognized as Executive of the Year by the Tech Council of Maryland (TCM), the state's largest technology and life science association. The award was presented at the 24th Annual Tech Awards, which celebrates individual and collective contributions of leaders and companies in the region.

"For the last 14 years, as the leader of Emergent BioSolutions since its founding in 1998, I have been continuously impressed by the caliber of talented professionals who collectively contribute to the company's success. Throughout our history of growth, one aspect has remained constant and central in our quest to make a positive impact in the community; that is the shared passion and commitment to live out our corporate mission – to protect life," said Mr. El-Hibri. "This award is dedicated to the Emergent team."

The Executive of the Year Award honors executives who have made outstanding contributions to their firm and have driven its success through their leadership skills. In evaluating the entries for this category, the panel of judges considered the individual who is an integral part of the firm's growth, skilled at taking calculated risks, and a leader in the Maryland technology or biotechnology community.

About Emergent BioSolutions Inc.

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information about the company may be found at www.emergentbiosolutions.com.